PARP inhibitorPhase 3 trialInvestigational
Rucaparib
How it works
Blocks an enzyme that helps repair damaged DNA in cancer cells, making them more susceptible to chemotherapy.
Cancer types
Prostate Cancer— Patients with BRCA1 or BRCA2 mutations
Ovarian Cancer— BRCA-mutated
Efficacy
Studies show that rucaparib can improve progression-free survival in patients with BRCA1/2-mutated ovarian cancer, with a median survival of approximately 10 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.